Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued access study of long-acting cabotegravir + rilpivirine in people with HIV-1
PACTR202404524950258Phase 4Recruiting
- Sponsor
- Johnson & Johnson
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of cabotegravir and rilpivirine in Human immunodeficiency virus infection type 1, sponsored by Johnson & Johnson. Primary endpoint: Number of Participants Who Continued to Receive Cabotegravir and Rilpivirine Long-Acting Injections. Started May 2024; status: recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on PACTR202404524950258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404524950258.